A phase 3 study of ME3208 for the treatment of chronic graft-versus-host disease in Japan

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2024 According to a Meiji Seika Pharma media release, results from this trial were presented on 14 June at the Congress of European Hematology Association (EHA2024) held in Madrid.
17 Jun 2024 Results presented in a Meiji Seika Pharma media release.
22 Mar 2024 According to Meiji Seika Pharma media release, positive findings from this study were presented at the 46th JSTCT (JSTC 2024) Annual Meeting of Japanese Society for Transplantation and Cellular Therapy held in Tokyo.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com